Mori H, Suzuki H (2019) Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil 25(1):6–14

Article  PubMed  PubMed Central  Google Scholar 

Tseng PH, Hung CS, Tu CH et al (2022) Association of incidence of acid-related upper gastrointestinal disorders with glycated hemoglobin level. J Clin Endocrinol Metab 107(6):e2563-2571

Article  PubMed  Google Scholar 

Savarino V, Antonioli L, Fornai M et al (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 16(5):401–410

Article  CAS  PubMed  Google Scholar 

Scarpignato C, Howden CW, Leifke E et al (2023) A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Aliment Pharmacol Ther 58(1):16–25

Article  CAS  PubMed  Google Scholar 

Liu C, Feng BC, Zhang Y et al (2019) The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis 20(10):503–511

Article  CAS  PubMed  Google Scholar 

St Onge E, Phillips B (2023) Vonoprazan: a new potassium-competitive acid blocker. J Pharm Technol 39(3):139–146

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sugano K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 11:1756283X17745776

Article  PubMed  PubMed Central  Google Scholar 

Jenkins H, Sakurai Y, Nishimura A et al (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41(7):636–648

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwakiri K, Fujiwara Y, Manabe N et al (2022) Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 57(4):267–285

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinucci I, Blandizzi C, Bodini G et al (2017) Vonoprazan fumarate for the management of acid related diseases. Expert Opin Pharmacother 18(11):1145–1152

Article  CAS  PubMed  Google Scholar 

Mermelstein J, Mermelstein AC, Chait MM (2020) Tegoprazan to treat gastroesophageal reflux disease. Drugs Today (Barc) 56(11):715–721

Article  CAS  PubMed  Google Scholar 

Kim JS, Seo SI, Kang SH et al (2023) Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil 29(1):58–64

Article  PubMed  PubMed Central  Google Scholar 

Ramani A, Merchant A, Cash BD (2023) Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease. Eur J Clin Pharmacol 79(8):1023–1029

Article  PubMed  Google Scholar 

Hwang JG, Jeon I, Park SA et al (2020) Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Ther 52(11–12):1648–1657

Article  CAS  PubMed  Google Scholar 

Zhou S, Xie L, Zhou C et al (2023) Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci 190:106578

Article  CAS  PubMed  Google Scholar 

Simadibrata DM, Syam AF, Lee YY (2022) A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol 37(12):2217–2228

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oshima T, Arai E, Taki M et al (2019) Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 49(2):140–146

Article  CAS  PubMed  Google Scholar 

Hagiwara T, Mukaisho K, Nakayama T et al (2015) Proton pump inhibitors and helicobacter pylori-associated pathogenesis. Asian Pac J Cancer Prev 16(4):1315–1319

Article  PubMed  Google Scholar 

Strand DS, Kim D, Peura DA (2017) 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 11(1):27–37

Article  CAS  PubMed  Google Scholar 

Scott DR, Munson KB, Marcus EA et al (2015) The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther 42(11–12):1315–1326

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang X, Li Y, Sun Y et al (2018) Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci 63(2):302–311

Article  CAS  PubMed  Google Scholar 

Oshima T, Miwa H (2018) Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 24(3):334–344

Article  PubMed  PubMed Central  Google Scholar 

Mulford DJ, Leifke E, Hibberd M et al (2022) The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev 11(2):278–284

Article  CAS  PubMed  Google Scholar 

Sue S, Maeda S (2021) Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication? Gut Liver 15(6):799–810

Article  PubMed  PubMed Central  Google Scholar 

Kiyotoki S, Nishikawa J, Sakaida I (2020) Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med 59(2):153–161

Article  CAS  PubMed  Google Scholar 

Inatomi N, Matsukawa J, Sakurai Y et al (2016) Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 168:12–22

Article  CAS  PubMed  Google Scholar 

Botton MR, Whirl-Carrillo M, Del Tredici AL et al (2021) Pharmvar genefocus: CYP2C19. Clin Pharmacol Ther 109(2):352–366

Article  PubMed  Google Scholar 

Scarpignato C, Hunt RH (2019) The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 35(4):344–355

Article  CAS  PubMed  Google Scholar 

Han S, Choi HY, Kim YH et al (2021) Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther 43(8):1371–1380

Article  CAS  PubMed  Google Scholar 

Abdel-Aziz Y, Metz DC, Howden CW (2021) Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 53(7):794–809

Article  CAS  PubMed  Google Scholar 

Tietto A, Faggin S, Scarpignato C et al (2025) Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opin Drug Metab Toxicol 21(1):53–68

Article  CAS  PubMed